Editorial & Opinion
Another prognostic marker for hepatocellular carcinoma.
العنوان: | Another prognostic marker for hepatocellular carcinoma. |
---|---|
المؤلفون: | Shao YY; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan. yuyunshao@gmail.com.; Department of Oncology, National Taiwan University Hospital, 7, Chung-Shan S. Rd., Taipei City, 10002, Taiwan. yuyunshao@gmail.com.; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan. yuyunshao@gmail.com. |
المصدر: | Hepatology international [Hepatol Int] 2023 Apr; Vol. 17 (2), pp. 279-280. Date of Electronic Publication: 2023 Mar 31. |
نوع المنشور: | Editorial; Comment |
اللغة: | English |
بيانات الدورية: | Publisher: Springer Country of Publication: United States NLM ID: 101304009 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1936-0541 (Electronic) Linking ISSN: 19360533 NLM ISO Abbreviation: Hepatol Int Subsets: MEDLINE |
أسماء مطبوعة: | Original Publication: New York, NY : Springer |
مواضيع طبية MeSH: | Carcinoma, Hepatocellular*/diagnosis , Carcinoma, Hepatocellular*/pathology , Liver Neoplasms*/diagnosis , Liver Neoplasms*/pathology, Humans ; Prognosis ; Biomarkers, Tumor |
التعليقات: | Comment on: Hepatol Int. 2023 Apr 25;:null. (PMID: 37186217) |
References: | Shao YY, Wang SY, Lin SM, Diagnosis G, Systemic TG. Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. J Formos Med Assoc. 2021;120:1051–1060. (PMID: 10.1016/j.jfma.2020.10.03133199101) Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–957. (PMID: 10.1056/NEJMoa081069919692680) Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408–1417. (PMID: 10.1056/NEJMoa080501919339720) Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509–2520. (PMID: 10.1056/NEJMoa1500596260282554481136) Bonneville R, Krook MA, Kautto EA, Miya J, Wing MR, Chen HZ, et al. Landscape of microsatellite instability across 39 cancer types. JCO Precis Oncol. 2017. https://doi.org/10.1200/PO.17.00073. (PMID: 10.1200/PO.17.00073298506535972025) El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389:2492–2502. (PMID: 10.1016/S0140-6736(17)31046-2284346487539326) Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19:940–952. (PMID: 10.1016/S1470-2045(18)30351-629875066) Shao YY, Liu TH, Lee YH, Hsu CH, Cheng AL. Modified CLIP with objective liver reserve assessment retains prognosis prediction for patients with advanced hepatocellular carcinoma. J Gastroenterol Hepatol. 2016;31:1336–1341. (PMID: 10.1111/jgh.1331226860846) Shao YY, Hsu CH, Cheng AL. Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: are we getting there? World J Gastroenterol. 2015;21:10336–10347. (PMID: 10.3748/wjg.v21.i36.10336264209604579880) Saeki I, Suehiro Y, Yamauchi Y, Hoshida T, Tanabe N, Oono T, et al. Methylated SEPT9 assay-based liquid biopsy as a biomarker in molecular targeted agent-treated hepatocellular carcinoma. Hepatol Int. 2023. |
المشرفين على المادة: | 0 (Biomarkers, Tumor) |
تواريخ الأحداث: | Date Created: 20230331 Date Completed: 20230424 Latest Revision: 20230926 |
رمز التحديث: | 20230927 |
DOI: | 10.1007/s12072-023-10504-1 |
PMID: | 37000388 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1936-0541 |
---|---|
DOI: | 10.1007/s12072-023-10504-1 |